

Memorandum

To:	All Medical, Nursing and Pharmacy staff, LCCH
Copies to:	EDMS, DDMS, EDNS, NUMs, Pharmacy
From:	Dr Julia Clark (Service Group Director – Infection Management and Prevention service, Immunology and Rheumatology) Dr Sonya Stacey (Director of Pharmacy, Lady Cilento Children's Hospital)
Contact no.:	3068 1912
Subject:	Mupirocin Calcium 2% Nasal Ointment (Bactroban Nasal ®) shortage

The LCCH pharmacy is currently unable to obtain stock of Mupirocin Calcium 2% Nasal Ointment (Bactroban Nasal ®).

Reason for the Shortage: GlaxoSmithKline states the shortage is due to manufacturing issues. GlaxoSmithKline is looking for an alternative supply source.[1]

Estimated Resupply Dates: Central Pharmacy has advised that this shortage is expected to continue until approximately the end of October 2018.

Safety: GlaxoSmithKline has advised that Mupirocin 2% topical ointment can safely be used intranasally for eradication of Staphylococcus Aureus nasal colonisation.[2] Do not share tubes of mupirocin ointment between patients to minimize the risk of cross-contamination.

In consultation with the Infection Management and Prevention service and the Pharmacy team the following arrangements will be made:

To conserve supplies, stock will be removed from ward imprest and kept in the Level 2 pharmacy department and reserved for use in priority cases on advice of the Infectious diseases team as specified in the table below:

Patient group	Eligibility	ID approval required	Number of tubes of Mupirocin 2% topical ointment to be provided per patient on outpatient prescription
Cardiac surgical patients	Eradication of Staphylococcus Aureus nasal colonisation according to CHQ guideline Paediatric Cardiac Surgical Antibiotic Prophylaxis	No	1 tube only
Renal dialysis patients	Eradication of Staphylococcus Aureus nasal colonisation according to CHQ Nursing Standard Peritoneal Dialysis Catheter: Management and Care of in Paediatric Patients	No	1 tube only
All other patients	MRSA/ Staph aureus decolonisation All other indications	Yes	If ID approved, 1 tube only. No ID approval – no supply will be provided.

Afterhours supply: Please contact the LCCH On call Pharmacist (note: prior approval by Afterhours NUM required) via LCCH Switchboard. Supply will be provided according to eligibility criteria and ID approval requirements specified above.

If you have any further questions or feel your case requires topical mupirocin, please contact the Infectious diseases team on (07) 3068 4421 or page via LCCH Switchboard.

References

1. GlaxoSmithKline (personal communications). May 23rd, 2018.
2. GlaxoSmithKline. Medical Information Request Number: 14503044 - Intranasal Use of Mupirocin Ointment – Summary. [Received May 23rd, 2018]



Sonya Stacey
Director of Pharmacy
25th of May 2018
